The lovastatin-treated rodent: a new model of barrier disruption and epidermal hyperplasia.
about
Pathobiology of the stratum corneum.Pseudo-acylceramide with linoleic acid produces selective recovery of diminished cutaneous barrier function in essential fatty acid-deficient rats and has an inhibitory effect on epidermal hyperplasiaMetabolic changes in skin caused by Scd1 deficiency: a focus on retinol metabolism.Ichthyosis in Sjögren-Larsson syndrome reflects defective barrier function due to abnormal lamellar body structure and secretion.Barrier function regulates epidermal DNA synthesis.Sphingolipids are required for mammalian epidermal barrier function. Inhibition of sphingolipid synthesis delays barrier recovery after acute perturbation.Thematic review series: skin lipids. The role of epidermal lipids in cutaneous permeability barrier homeostasis.The role of fatty aldehyde dehydrogenase in epidermal structure and function.Pathogenesis-based therapy reverses cutaneous abnormalities in an inherited disorder of distal cholesterol metabolismGlucocorticoids accelerate fetal maturation of the epidermal permeability barrier in the ratStratum corneum defensive functions: an integrated view.The emerging role of peptides and lipids as antimicrobial epidermal barriers and modulators of local inflammation.Abnormal barrier function in the pathogenesis of ichthyosis: therapeutic implications for lipid metabolic disorders.Lipids and skin barrier function--a clinical perspective.Co-regulation and interdependence of the mammalian epidermal permeability and antimicrobial barriers.Genetics and prospective therapeutic targets for Sjögren-Larsson Syndrome.Fatty aldehyde and fatty alcohol metabolism: review and importance for epidermal structure and function.Local Application of Statins Significantly Reduced Hypertrophic Scarring in a Rabbit Ear Model.Lamellar bodies as delivery systems of hydrolytic enzymes: implications for normal and abnormal desquamation.Lovastatin enhances the photocytotoxicity of UVA radiation towards cultured N.C.T.C. 2544 human keratinocytes: prevention by cholesterol supplementation and by a cathepsin inhibitor.Topical simvastatin promotes healing of Staphylococcus aureus-contaminated cutaneous wounds.Morphology of lipid alterations in the epidermis: a review.The in vitro effect of hydroxychloroquine on skin morphology in psoriasis.Pathogenesis of the cutaneous phenotype in inherited disorders of cholesterol metabolism: Therapeutic implications for topical treatment of these disorders.Epidermal Dysfunction Leads to an Age-Associated Increase in Levels of Serum Inflammatory Cytokines.A woman with axillary red-brown plaques.Spiny keratoderma: a common under-reported dermatosis.Reevaluation of the non-lesional dry skin in atopic dermatitis by acute barrier disruption: an abnormal permeability barrier homeostasis with defective processing to generate ceramide.Reduced skin lipid content in obese Japanese women mediated by decreased expression of rate-limiting lipogenic enzymes.
P2860
Q24539142-2F2AA611-32E8-4B34-9347-7BC7DF7829A4Q28369339-6AF67074-E257-4712-AE5D-9A608A1F2D9DQ33900400-46923B25-BC89-4FAF-868E-9FD1DC6C536EQ33940796-3820B8E2-11AF-4829-8EC0-A78A7239D170Q34188256-D5A72790-5A01-4AAC-A298-791EFACED0FDQ34205361-2ADFAFFC-4A47-430B-A6F4-969D0BBF779BQ34687966-A91ED13E-7EC9-45DD-9FDC-7D942F73D5CEQ35050721-E516B27B-1801-48F1-8B7C-E0E15579ED82Q35350057-173E7222-95C2-4CA2-BCA6-116FD473E36CQ35611143-ACA6DA89-B28B-48CF-A08D-9858EE3E0B6DQ36228049-15BB8805-9DC8-472A-B580-5B18E9479164Q36587156-EBD76728-7E36-4B67-BD88-CAC3B61D6CD4Q36713839-6B6C1E0E-317B-4FCB-ACBC-E9421E0C67D7Q37139810-22AB430A-2EE3-4444-995B-100C0A412088Q37164058-3DF0091A-C7BF-49D3-B874-70E24DE836A7Q37185656-462B5AE2-1F75-4366-A1E9-3A22C8126512Q37714304-A91E3AD8-706E-4924-BFF7-7E6A981AAF81Q40984955-7FE5489A-7271-47F7-8AD7-631E4D019ADDQ41116794-189849DD-DEFF-497F-A066-76D045BF199FQ41311274-A650228D-1E31-40FA-A8CD-DF92F8F187E3Q41442433-47D3A8FD-1082-4827-9523-AFA9F1B8FABCQ41465321-2D0AAB5B-19C5-4306-B863-21C14B402E0EQ41924353-D5F20382-2FD7-4708-B3A7-5B78A9D19508Q42761501-3E60A82B-0746-4767-90A6-77C8B898791EQ46517032-F9BE4016-FE0D-4ABF-BD67-159395C6C87EQ50483707-306C1B14-3856-479D-A009-5E52771DE3A7Q50874782-B7D88B91-075C-47C7-81F5-BEB87DCE6ACBQ52645660-85D74E04-E27E-4DF7-8681-28C206F9C05CQ54095639-E493953B-4F97-4E21-9666-D5EF6D996B86
P2860
The lovastatin-treated rodent: a new model of barrier disruption and epidermal hyperplasia.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh
1991年學術文章
@zh-hant
name
The lovastatin-treated rodent: ...... ion and epidermal hyperplasia.
@en
The lovastatin-treated rodent: ...... ion and epidermal hyperplasia.
@nl
type
label
The lovastatin-treated rodent: ...... ion and epidermal hyperplasia.
@en
The lovastatin-treated rodent: ...... ion and epidermal hyperplasia.
@nl
prefLabel
The lovastatin-treated rodent: ...... ion and epidermal hyperplasia.
@en
The lovastatin-treated rodent: ...... ion and epidermal hyperplasia.
@nl
P2093
P1476
The lovastatin-treated rodent: ...... ion and epidermal hyperplasia.
@en
P2093
P2888
P304
P356
10.1111/1523-1747.EP12461153
P407
P577
1991-02-01T00:00:00Z
P5875
P6179
1019756854